Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025Blood

Impact of induction response and co-mutations on transplant outcomes in AML with myelodysplasia-related gene mutations: A multicenter retrospective study

View Full Paper
Ask AI
Bookmark
Share

Authors

XCXing ChenXHXiaoxia Hu

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study shows hypomethylating agents improved CR rates in AML with mutations, indicating better transplant outcomes.

Key Points

  • Complete remission rates reached 56.6% in acute myeloid leukemia patients receiving induction therapy involving hypomethylating agents and venetoclax.
  • Two-year overall survival was reported at 77.4%, while two-year relapse-free survival reached 70% after allo-HSCT.
  • Observational analysis focusing on patients diagnosed with acute myeloid leukemia involved co-mutations like RUNX1 and TP53.
  • Epigenetic regulator mutations were linked to a decrease in overall survival, emphasizing their role in AMK transplant outcomes.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da57https://doi.org/10.1182/blood-2025-3394
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Impact of induction regimen and co-mutations on outcomes in AML with myelodysplasia-related changes2025
  2. 2Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWP2025
  3. 3Unifying the classification of acute myeloid leukemia, myelodysplasia-related: A multi-institutional experience2025 · 1 citations
  4. 4Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP2025
  5. 5TP53, EZH2, or RUNX1 mutations predict poor outcomes in ELN 2022 adverse risk group of adult AML patients undergoing allo-HSCT2025